PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 27241169-8 2016 Combined treatment with hypericin and YM155 led to a more severe dissipation of the mitochondrial membrane potential and caused an increase in caspase-3 activation and subsequent PARP cleavage. YM 155 38-43 caspase 3 Homo sapiens 143-152 20517311-6 2010 The combination of YM155 and platinum compounds also induced synergistic increases both in the number of apoptotic cells and in the activity of caspase-3. YM 155 19-24 caspase 3 Homo sapiens 144-153 29689274-8 2018 YM155 induced increases in pro-apoptotic proteins (Bax and Bad), diminished anti-apoptotic proteins (Mcl-1, Bcl-xl, XIAP, survivin) and initiated cleavage of apoptotic marker proteins caspase 3 and PARP. YM 155 0-5 caspase 3 Homo sapiens 184-193 25948188-7 2015 With the increasing of YM155 concentration and prolonging of action time, the expression levels of mRNA and protein of survivin and BCL-2 decreased, while the expression levels of caspase-3, PARP, beclin1 and LC-3 increased. YM 155 23-28 caspase 3 Homo sapiens 180-189 26118775-3 2015 YM155 induced apoptosis through activation of intrinsic and extrinsic pathways that also culminated in caspase-3 activity and PARP cleavage. YM 155 0-5 caspase 3 Homo sapiens 103-112 26081496-4 2015 It was found that YM155 inhibited cell proliferation, colony formation, migration and invasion, induced cell apoptosis, as well as increased caspase-3, -8 and -9 activity in the OS cell lines in a dose-dependent manner. YM 155 18-23 caspase 3 Homo sapiens 141-161 25948188-8 2015 Compared with the YM155 group, the protein levels of LC-3 and caspase-3 were lower in YM155 combined with 3-MA group. YM 155 18-23 caspase 3 Homo sapiens 62-71 25220225-5 2015 The ER(-) /HER2(+) SK-BR-3 breast cancer cells and the triple-negative/caspase-3-expressing metastatic aggressive MDA-MB-231 breast cancer cells were also sensitive to YM155 with IC50 values in the low nanomolar range. YM 155 168-173 caspase 3 Homo sapiens 71-80 25220225-8 2015 CONCLUSIONS AND IMPLICATIONS: YM155 is a potent survivin inhibitor that has potential for the management of various breast cancer subtypes regardless of the expression of ER, HER2 and caspase-3. YM 155 30-35 caspase 3 Homo sapiens 184-193 24432379-3 2013 The combination of YM155 with docetaxel showed synergistic antiproliferative and caspase 3/7-inducing effects in MRK-nu-1 and MDA-MB-453 human TNBC cell lines in vitro. YM 155 19-24 caspase 3 Homo sapiens 81-90 23618862-6 2013 Treatment of HL-60 and U937 cells with YM155 induced apoptosis concomitant with the activation of caspase-8 and caspase-3. YM 155 39-44 caspase 3 Homo sapiens 112-121 23618862-8 2013 When cells were pretreated with Z-IETD-FMK, the activation of caspase-3 was completely abolished, suggesting that caspase-8 may be involved in the activation of caspase-3 during YM155-induced apoptosis. YM 155 178-183 caspase 3 Homo sapiens 62-71 23618862-8 2013 When cells were pretreated with Z-IETD-FMK, the activation of caspase-3 was completely abolished, suggesting that caspase-8 may be involved in the activation of caspase-3 during YM155-induced apoptosis. YM 155 178-183 caspase 3 Homo sapiens 161-170 23267699-10 2012 Annexin V assay, cell cycle, and activation of caspase-3 demonstrates that YM155 induced apoptosis in SK-NEP-1 cells. YM 155 75-80 caspase 3 Homo sapiens 47-56